Research Topics
Species | Kah Whye PengSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Strategies for targeting therapeutic gene deliveryK W Peng
Molecular Medicine Program, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Mol Med Today 5:448-53. 1999..This review summarizes recent strategies to alter vector tropism for targeted gene delivery...- Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic miceKah Whye Peng
Molecular Medicine Program, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Hum Gene Ther 14:1565-77. 2003.... - Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell markerKah Whye Peng
Molecular Medicine Program, Mayo Foundation, Rochester, MN 55905, USA
Blood 101:2557-62. 2003..Tumorigenicity of CHO-CD38 cells in immunocompromised mice was significantly attenuated by MV-alpha CD38, resulting in enhanced survival of these mice compared with the control group... - Engineering oncolytic measles virus to circumvent the intracellular innate immune responseIana Haralambieva
1Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Mol Ther 15:588-97. 2007..These results indicate that oncolytic viruses are subject to control by the innate immune defenses of human tumor cells and may therefore be more effective if their natural ability to combat innate immunity is maintained... - Intraperitoneal therapy of ovarian cancer using an engineered measles virusKah Whye Peng
Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 62:4656-62. 2002..Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer... - Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomasGeorgia Paraskevakou
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Mol Ther 15:677-86. 2007.... - Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy modelEmily K Mader
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Cancer Res 15:7246-55. 2009..Hence, we hypothesized that measles virotherapy of ovarian cancer in measles-immune mice might be superior if MV-infected mesenchymal stem cell (MSC) carriers are used... - Interaction of measles virus vectors with Auger electron emitting radioisotopesDavid Dingli
Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Biochem Biophys Res Commun 337:22-9. 2005..MV-NICE does not replicate faster in the presence of radiation. Auger electron emitting isotopes effectively stop propagation of MV vectors expressing NIS in vitro. Additional work is necessary to translate these observations in vivo... - Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancerChunsheng Liu
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Prostate 69:1128-41. 2009.... - Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myelomaKah Whye Peng
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
Am J Hematol 84:401-7. 2009..Thus, TAM are a universal stromal component of the plasmacytomas of myeloma patients and may offer a promising new target for therapeutic exploitation. Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc... - Oncolytic measles virus strains in the treatment of gliomasCory Allen
Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA
Expert Opin Biol Ther 8:213-20. 2008..Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy... - Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporterDavid Dingli
Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Blood 103:1641-6. 2004..Testing in other radiosensitive cancers is warranted... - Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporterKosei Hasegawa
Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Clin Cancer Res 12:1868-75. 2006..This has important implications for the clinical development of oncolytic measles viruses... - Affinity thresholds for membrane fusion triggering by viral glycoproteinsKosei Hasegawa
Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
J Virol 81:13149-57. 2007..For a given cell surface receptor density, there is an affinity threshold above which cell-cell fusion proceeds efficiently. Suprathreshold affinities do not further enhance the efficiency of membrane fusion... - Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genomeLinh Pham
Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Gene Med 11:197-206. 2009.... - Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivoHooi Tin Ong
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Mol Ther 17:1012-21. 2009..To our knowledge, this is the first report demonstrating that oncolytic MVs can be engineered to target the lumenal endothelial surface of newly formed blood vessels when administered intravenously in living animals... - Mutations in the stalk region of the measles virus hemagglutinin inhibit syncytium formation but not virus entryMatthew K Ennis
Department of Molecular Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
J Virol 84:10913-7. 2010..We show that after binding of MV to its receptor, H-F dissociation is required for productive infection... - Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancerEvanthia Galanis
Division of Medical Oncology, Department of Molecular Medicine, Mayo Clinic, Gonda 10 141, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Res 70:875-82. 2010..Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients... - Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriersChunsheng Liu
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Mol Ther 18:1155-64. 2010..Hence, we demonstrate for the first time that systemically administered cells can serve as MV carriers and prolonged survival of mice with pre-existing antimeasles antibodies... - Antibody-targeted cell fusionTakafumi Nakamura
Molecular Medicine Program, Mayo Foundation, 200 First St. SW, Rochester, Minnesota 55905, USA
Nat Biotechnol 22:331-6. 2004.... - Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiformeLoi K Phuong
Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 63:2462-9. 2003..c. and orthotopic U87 animal models. Monitoring CEA levels in the serum can serve as a low-risk method of detecting viral gene expression during treatment, and could allow dose optimization and individualization of treatment... - Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptidesKah-Whye Peng
Molecular Medicine Program, Mayo Foundation, Rochester, Minnesota, USA
Nat Med 8:527-31. 2002..Oncolytic viruses expressing inert soluble marker polypeptides should greatly facilitate the rational development of effective, individually tailored cancer virotherapy... - Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primatesNathan Jenks
Toxicology and Pharmacology Laboratory, Mayo Clinic, Rochester, MN 55905, USA
Hum Gene Ther 21:451-62. 2010..On the basis of these studies, we will be proposing a cautious approach to dose escalation in a phase I clinical trial among patients with HCC... - High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virusBambi D Anderson
Molecular Medicine Program, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Cancer Res 64:4919-26. 2004..Discrimination between high and low CD46 receptor density provides a compelling basis for the oncolytic specificity of MV-Edm and establishes MV-Edm as a promising CD46-targeted cancer therapeutic agent... - Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomasCory Allen
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Gene Med 6:1216-27. 2004..Given the high frequency of MMP overexpression in gliomas, AdM40 represents a potentially promising agent in the gene therapy of these tumors... - Reengineering paramyxovirus tropismElizabeth M Hadac
Molecular Medicine Program, Mayo Clinic Rochester, Rochester, MN 55905, USA
Virology 329:217-25. 2004..We conclude that paramyxoviruses have a remarkably flexible and adaptable entry mechanism... - Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificityCory Allen
Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 66:11840-50. 2006.... - Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinomaBoris Blechacz
Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
Hepatology 44:1465-77. 2006..MV-Edm expressing CEA or hNIS elicited oncolytic effects in human HCC cell lines in vitro and in vivo, enabling the spread of the virus to be monitored in a noninvasive manner... - Viruses as anticancer drugsStephen J Russell
Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Trends Pharmacol Sci 28:326-33. 2007..This review introduces concepts relevant to the use of viruses as anticancer drugs, emphasizing targeting mechanisms as well as safety and efficacy issues that are currently limiting their clinical success... - Oncolytic measles virus targets high CD46 expression on multiple myeloma cellsHooi Tin Ong
Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Exp Hematol 34:713-20. 2006.... - The utility of cells as vehicles for oncolytic virus therapiesStephen J Russell
Mayo Clinic, Department of Molecular Medicine, 200 1st Street SW, Rochester, MN 55905, USA
Curr Opin Mol Ther 10:380-6. 2008..Aside from their virus chaperoning capabilities, certain carrier cell types may exert additional antitumor activities that operate in synergy with the oncolytic virus infection to mediate tumor regression... - Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myelomaApollina Goel
Molecular Medicine Program, College of Medicine, Mayo Clinic, Guggenheim 1833, 200 First Street SW, Rochester, MN 55905, USA
Blood 107:4063-70. 2006..PS-341 is a potent, selective in vivo radiosensitizer that may substantially affect the efficacy of skeletal-targeted radiotherapy in multiple myeloma... - Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancerRae Myers
Toxicology Core, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Cancer Gene Ther 12:593-9. 2005..All three viruses demonstrated equivalent antitumor potency. Commercially available Moraten measles and Jeryl-Lynn mumps vaccines warrant further investigation as potential anticancer agents... - Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapyHongtao Li
1 Mayo Clinic Department of Molecular Medicine, Rochester, MN 55905
Hum Gene Ther 23:295-301. 2012..MV-NIS could be a promising new anticancer agent that may substantially enhance the outcomes of standard therapy after intratumoral administration in patients with locally advanced SCCHN... - Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahariToshie Sakuma
Department of Molecular Medicine, Mayo Clinic, Guggenheim 18 11c, 200 First Street, SW, Rochester, MN 55905, USA
J Virol 85:1205-13. 2011..These data support the use of Mus pahari as a model for XMRV pathogenesis and as a platform for vaccine and drug development against this potential human pathogen... - The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancerKosei Hasegawa
Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Clin Cancer Res 12:6170-8. 2006..and i.p.). CONCLUSIONS: A FR-exclusive ovarian cancer targeted oncolytic virus was generated and shown to be therapeutically effective, thus introducing a new modality for FR targeting and a candidate measles virus for clinical testing... - Primer on medical genomics. Part X: Gene therapyStephen J Russell
Molecular Medicine Program, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 78:1370-83. 2003..This review should serve as an introduction to the subject of gene therapy for clinician investigators, physicians and medical scientists in training, practicing clinicians, and other students of medicine... - Rescue and propagation of fully retargeted oncolytic measles virusesTakafumi Nakamura
Nat Biotechnol 23:209-14. 2005..These data provide an in vivo demonstration of antibody-directed tumor destruction by retargeted oncolytic viruses... - In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46Hongjie Wang
Division of Medical Genetics, University of Washington, Seattle, Washington 98195, USA
J Virol 82:10567-79. 2008..We conclude that Ad5/35 vectors with increased affinity to CD46 have an advantage in competing with non-CD46-mediated sequestration of vector particles after intravenous injection...
Research Grants
- Retargeted Oncolytic Measles Viruses Displaying Single-Chain AntibodiesKah Whye Peng; Fiscal Year: 2007..3) To determine the relationship between affinity of displayed scFv and virus entry or cell fusion of retargeted MVs. ..
- 4th International Conference on Oncolytic Viruses as Cancer TherapeuticsKah Whye Peng; Fiscal Year: 2007..It also provides a forum for trainees to present their work and obtain constructive feedback from senior scientists. This provides an important training ground for tomorrow's scientists. ..
- Retargeted Oncolytic Measles Viruses Displaying Single-Chain AntibodiesKah Whye Peng; Fiscal Year: 2009..3) To determine the relationship between affinity of displayed scFv and virus entry or cell fusion of retargeted MVs. ..
- Enhancing localization of therapeutic viruses and cells to tumor sitesKah Whye Peng; Fiscal Year: 2010..This grant seeks to improve the tumor localization of measles viruses and virus infected cell carriers by adding vascular binding motifs on their surfaces to enhance their attachment/arrest at tumor neovessels and tumor sites. ..
- Retargeted Oncolytic Measles Viruses Displaying Single-Chain AntibodiesKah Whye Peng; Fiscal Year: 2010..3) To determine the relationship between affinity of displayed scFv and virus entry or cell fusion of retargeted MVs. ..